OUR SERVICES ON DEMAND
Our strategic screening process is
designed to identify the most promising pharmacological candidates for new drug development.
End-to-end strategic screening using artificial intelligence begins with a large pool of compounds, potentially consisting of thousands or even millions of molecules, and narrows it down to a prioritized list of candidate compounds. This process is based on a series of predefined criteria, including the compound's potential efficacy, safety, ease of production, originality, and commercial potential. These candidates are then tested in the laboratory to determine their pharmacological properties. Compounds that exhibit the desired characteristics undergo further testing and evaluation, with the ultimate goal of identifying one or a few candidates for drug development.
OUR SERVICES ON DEMAND
Our molecule sub-screening service focuses
on the refinement and repurposing of screened drugs.
We offer a complete process for refining and repurposing previously approved drugs or those in development for new medical applications. This process, known as "drug repurposing" or "repositioning," involves identifying new uses for existing drugs beyond their original approved indications. This includes proprietary drugs from pharmaceutical companies that did not pass clinical trials.
We have applied for two European patents to protect our unique approach and for the protection of therapeutic XCI-reactivating molecules and we are in progress to apply for another patent for our proprietary AI-powered RNA modifying molecule discovery platform.
